There is a lot of fragmentation in European healthcare systems. Some of them have very comprehensive methodologies to assess the value of medicines, others are lacking these processes. Moreover, drug supply and prices are negotiated between stakeholders without making discounts and rebates publicly available.
Assessing the economic benefit of drugs is crucial today.
The last link is very interesting as it will land you on the page of the European Observatory on Health Systems & Policies website where you could find resourceful reports on health systems currently established in Europe.